AbbVie Submits Rinvoq Application to FDA for Severe Alopecia Areata
ABBV is trading near its 52-week low of $176.57 (12% above the low).
Summary
AbbVie has submitted an application to the FDA for its drug Upadacitinib (Rinvoq®) to treat adults and adolescents with severe alopecia areata. This regulatory filing is a positive development, as it seeks to expand the indications for a key growth driver for AbbVie, opening up a new potential market. The submission is supported by positive Phase 3 data, indicating the drug met its primary endpoint in this condition. While not an approval, this is a material step towards broadening Rinvoq's market reach and contributing to AbbVie's long-term revenue growth, following recent news about Rinvoq's superiority in rheumatoid arthritis.
At the time of this announcement, ABBV was trading at $198.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $350.2B. The 52-week trading range was $176.57 to $244.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.